Distinguishing Circulating Tumor from Normal Cell-Free DNA

Fragments of circulating DNA from tumors are around 20 to 30 base pairs shorter than those from healthy cells, researchers report.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Untreated glioblastoma WIKIMEDIA, AFIPPieces of tumor DNA circulating in the bloodstream are generally shorter than circulating DNA fragments derived from healthy cells, scientists reported this week (July 18) in PLOS Genetics.

Researchers from the University of Washington and the University of Utah observed the DNA difference by analyzing fragments derived from human glioblastoma and hepatocellular carcinoma cells transplanted in rats. The team observed that the human circulating tumor DNA was typically 134 to 144 base pairs long, while the rat circulating DNA was typically 167 base pairs long.

The scientists were then able to confirm this length difference in people: a cohort of 15 patients with lung cancer compared against nine healthy individuals, GenomeWeb reported.

Human circulating tumor DNA “was overall consistently shorter than the fragment length of normal cell-free DNA,” the authors wrote in their paper.

The findings could help improve cancer diagnosis and treatment prescription using liquid biopsies—a minimally invasive cancer detection method that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Alison F. Takemura

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide